APLS Q4 2021 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M-75.9% YoY

Gross Profit

$60M99.3% margin

Operating Income

-$89M-148.3% margin

Net Income

-$148M-245.4% margin

EPS (Diluted)

$-1.73

QoQ Revenue Growth

+967.1%

Cash Flow

Operating Cash Flow

-$112M

Free Cash Flow

-$113M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$882M

Total Liabilities

$683M

Stockholders' Equity

$199M

Cash & Equivalents

$640M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$250M	-75.9%
Gross Profit	$60M	$250M	-76.0%
Operating Income	-$89M	$130M	-168.7%
Net Income	-$148M	$78M	-289.0%

Revenue Segments

Licensing And Other Revenue

$51M85%

Product

$9M15%